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Discoid Lupus Erythematosus with Hydroxychloroquine-Induced
Hyperpigmentation
Olabola Awosika, MD, MS, Bhavnit K. Bhatia, MD, and Jungho Kwon, MD
Department of Dermatology, Henry Ford Health System, Detroit, MI

History
• A 65-year-old African American female presented for
follow-up of an 8-year history of biopsy proven discoid
lupus erythematosus (DLE) of the bilateral upper
eyelids.
• She had significant re-pigmentation of the eyelids on
hydroxychloroquine 200 mg once daily, tacrolimus 0.1%
ointment, and daily SPF 50 sunscreen.
• However, in the last year, she noted progressive
hyperpigmentation over the face, neck, and chest.
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Examination
• On the bilateral eyelids, there were ill-defined
hypopigmented macules with areas of significant repigmentation.
• On the face, neck, and upper chest, there were confluent,
dark brown to gray, hyperpigmented patches in a photodistributed pattern.

Histopathology

Figure 1: Pathology specimen revealing brown coarsely granular
pigment deposits within histiocytes and extracellularly, along the
epidermal basal layer and throughout the superficial dermis.

Figure 2. A) Bilateral upper eyelids with hypopigmented macules and significant

repigmentation. Gray to brown confluent hyperpigmented patches are also noted
on the face, neck, and upper chest. B) 7 months after discontinuing
hydroxychloroquine and starting heliocare and strict photoprotection, there is
decrease in hyperpigmentation.

Course and Therapy
• Punch biopsy was taken of the neck and showed the following:
–Hematoxylin and eosin stain demonstrated histiocytic and extracellular
brown coarse granular pigment deposits along the epidermal basal layer
and superficial dermis.
–Fontana-Masson stain highlighted these granules, supporting the presence
of melanin.
–A Perl’s iron stain for hemosiderin was negative.
–These changes were consistent with drug induced pigmentary alteration
secondary to hydroxychloroquine.
• At the time of presentation for worsening hyperpigmentation, the patient
had been on hydroxychloroquine for 3 years with stabilization of her
DLE.
• After biopsy confirmation that her pigmentation was likely induced by
hydroxychloroquine, it was discontinued.
• The patient was then started on strict photoprotection with daily use of
broad spectrum sunscreen and heliocare daily, with slow improvement
of hyperpigmentation over the past year.
• The patient was also started on tacrolimus 0.1% ointment daily the
superior eyelids, to alternate with triamcinolone 0.1% ointment or
hydrocortisone 2.5% ointment daily for flares of DLE.

Discussion
• One of the most common side effects of antimalarial
medications is cutaneous hyperpigmentation.
• The prevalence of this side effect in DLE is unknown,
but it can occur in up to 25% of patients with systemic
lupus erythematosus. The majority of cases are due to
chloroquine, although there have been reports with use
of hydroxychloroquine.
• Onset of antimalarial-induced pigmentation commonly
occurs after 4 months of use, ranging from 3 months to
22 years for hydroxychloroquine induced-pigmentation.
• Risk factors may include skin phototypes V or VI,
concomitant use of oral anticoagulants or antiplatelet
agents, and sun exposure.
• Discoloration due to chloroquine or hydroxychloroquine
will appear as slate-gray to blue-black patches, with
predominance for the anterior shins. Other common sites
include the face, forearms, hard palate, gingivae, or the
nail beds.
• Histopathology of antimalarial-induced pigmentation
demonstrates yellow to brown pigmented granules
throughout the dermis in macrophages and fibroblasts.
• Special stains, such as the Fontana-Mason and Perl’s
staining, will display the presence of melanin and
hemosiderin, respectively, within the dermis. Biopsies of
hydroxychloroquine-induced pigmentation may only
demonstrate presence of melanin and not hemosiderin.
• There is no consensus on treatment for pigmentation
induced by antimalarials. Discontinuing use of
antimalarial medications will reduce pigmentation.
However, the hyperpigmentation typically does not
completely resolve.
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